While this unexpected reduction of CSNK2B by CX-4945 makes it difficult to dissect the role played by the catalytic CK2 subunits versus CSNK2B in control of IRF1 activity (Supplementary Figure S2A), CX-4945 treatment in human hepatoma (Huh-7.5) cells did not affect CSNK2B abundance and dose-dependently suppressed HAV replication (Figure 2G, H). The gene discussed is CSNK2B; the disease is hepatocellular carcinoma.